Skip to main content
Signal8
Launch Terminal

Solid Biosciences Inc. (SLDB)

Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles. The company is also progressing with SGT-003, which represents a next-generation gene transfer therapy intended for DMD. Beyond specific drug candidates, Solid Biosciences is actively developing innovative platform technologies, such as "dual gene expression," a technique that allows for multiple therapeutic genes to be bundled into a single viral vector, and researching new capsid designs. The company maintains a strategic alliance through a collaboration and license agreement with Ultragenyx Pharmaceutical Inc., focusing on the joint development and market introduction of novel gene therapies for Duchenne Muscular Dystrophy. Founded in 2013, Solid Biosciences Inc. conducts its operations from its headquarters in Cambridge, Massachusetts.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Solid Biosciences Inc. logo

Solid Biosciences Inc.

NASDAQ:SLDBHealthcare
-2.97%$6.20
AH$6.25+0.81%vs close
Mkt Cap$664.8M
Float69.29M
O/S107.23M
Vol
$ Vol
RVOL
Inst Own-
SI17.8%
Earnings
Dilution
Solid Biosciences Inc. logoNASDAQ:SLDB$6.20-2.97%
Upcoming Catalysts
  • SGT-212READOUT
    Cash runway at this date: 12mo
    Q1 2027~21w8-K
Phase Distribution
6 lead-sponsored trials·5 active·1 completed
Phase 12
Phase 1/22
Phase 31
Not applicable1
(1 more as collaborator)

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Recruiting

    A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)

    SGT-003, Placebo

    Duchenne Muscular Dystrophy

    Enrollment
    80
    Start
    Oct 2025
    Primary Completion
    Jan 2029est.
    Completion
    Jan 2034est.
    NCT07160634
  • Phase 1/2
    Active, not recruiting

    Microdystrophin Gene Transfer Study in Adolescents and Children With DMD

    SGT-001

    Duchenne Muscular Dystrophy

    Enrollment
    12
    Start
    Dec 2017
    Primary Completion
    Nov 2026est.
    Completion
    Nov 2026est.
    NCT03368742
  • Phase 1/2
    Recruiting

    A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)

    SGT-003

    Duchenne Muscular Dystrophy

    Enrollment
    60
    Start
    May 2024
    Primary Completion
    May 2027est.
    Completion
    May 2031est.
    NCT06138639
  • Phase 1
    Recruiting

    A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

    SGT-501

    Catecholaminergic Polymorphic Ventricular Tachycardia

    Enrollment
    18
    Start
    Feb 2026
    Primary Completion
    Jun 2027est.
    Completion
    May 2031est.
    NCT07148089
  • Phase 1
    Recruiting

    A Study of SGT-212 Gene Therapy in Friedreich's Ataxia

    SGT-212ORPHAN DRUG

    Friedreich's Ataxia (FA)

    Enrollment
    10
    Start
    Oct 2025
    Primary Completion
    Mar 2028est.
    Completion
    Feb 2032est.
    NCT07180355
  • Observational
    Completed

    Evaluation of Home Based Assessments on Participants With DMD

    Wearable Device, Duchenne Video Assessment (DVA)

    Duchenne Muscular Dystrophy

    Enrollment
    17
    Start
    Oct 2022
    Primary Completion
    Apr 2023
    Completion
    Apr 2023
    NCT05657938
Search ClinicalTrials.gov for “Solid Biosciences”